What is the 13F Pro Quality Score for EBS?

13F Pro ranks Emergent BioSolutions Inc. (EBS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EBS's current score at https://13fpro.ai/company/EBS (free sign-up required for the full ranking).

Which hedge funds own the most EBS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of EBS include BlackRock,, DIMENSIONAL FUND ADVISORS, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/EBS as soon as new 13F filings post.

Where does 13F Pro source EBS data?

All Emergent BioSolutions Inc. fundamentals and ownership data come directly from SEC EDGAR. Emergent BioSolutions Inc. files with the SEC under CIK 1367644. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EBS in?

Emergent BioSolutions Inc. (EBS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is EBS research updated on 13F Pro?

EBS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Emergent BioSolutions Inc.(EBS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1367644 EBS stock profile & AI dashboard →

13F Pro Quality Score

31.2/100

Rank #2,463 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

4.1/100

Profitability

14.0/100

Balance Sheet

14.3/100

Earnings Quality

56.2/100

Free Cash Flow

57.9/100

Institutional Flow

66.6/100

Revenue Scale

45.1/100

Dilution Risk

38.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why EBS Scores 31/100

exact factor attribution · 2026-09-11

EBS's composite is driven by free cash flow, held back by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Free cash flow

+1.2 pts

58th pct

Institutional flow

+0.8 pts

67th pct

Earnings quality

+0.6 pts

56th pct

Shareholder dilution

-0.6 pts

39th pct

Scale

-0.7 pts

45th pct

Earnings growth

-2.0 pts

10th pct

Capital efficiency

-3.6 pts

14th pct

Profitability

-5.4 pts

14th pct

Revenue growth

-9.2 pts

4th pct

Latest change (2026-08-11): 51 → 34 · ↓ Profit margin 84→28; ↓ Capital efficiency 84→33

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in EBS

Events flagged as statistical outliers against EBS's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-11
EBS quality score dropped 17 points (51→34) on a new filing
View source filing →

EBS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Emergent BioSolutions Inc. (EBS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EBS at 31.2/100 on a 32-signal composite quality model, placing it at rank #2,463 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (4.1) and profitability (14.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Emergent BioSolutions Inc. reports quarterly revenue of $234.3M, net income of $-180.2M, free cash flow of $54.0M. Top institutional holders of EBS by reported 13-F value include BlackRock, DIMENSIONAL FUND ADVISORS, STATE STREET, based on the most recent SEC filings. EBS trades on the NYSE exchange and files with the SEC under CIK 1367644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EBS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Emergent BioSolutions Inc. directly from SEC EDGAR. Emergent BioSolutions Inc.'s 13F Pro composite quality score has ranged between 17 and 77 since 2021, currently 31.2 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Emergent BioSolutions Inc.

Quirks, history, and lore behind EBS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · focused on public health threats · listed on NYSE · headquartered in Maryland.
2
The Numbers
Annual revenue in the range of roughly $1 billion, heavily dependent on U.S. government contracts — when Washington orders, this company ships.
3
The History
Formed in 2004 through the merger of two biodefense-focused firms, it was built from the ground up to serve as a strategic national stockpile supplier.
4
The Secret
Its biggest customer is essentially the federal government, making quarterly earnings about as predictable as a congressional budget — which is to say, not very.
5
The Lore
The company faced intense scrutiny after anthrax vaccine quality issues led to a consent decree with the FDA, yet it remained the U.S.'s primary supplier of biodefense countermeasures.
6
The Giveaway
It makes the anthrax vaccine BioThrax, smallpox treatments, and other medical countermeasures for biological and chemical threats — the company governments call when the nightmare scenarios aren't hypothetical.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$234.3M

Net Income

Q2 2026

$-180.2M

Free Cash Flow

Q2 2026

$54.0M

ROIC

Q2 2026

-53.7%

D/E Ratio

Q2 2026

1.73

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-28.8% YoY

$742.9MFY 2025

FY22 $1.12BFY23 $1.05BFY24 $1.04BFY25 $742.9M

Net Income

+127.6% YoY

$52.6MFY 2025

FY22 $-211.6MFY23 $-760.5MFY24 $-190.6MFY25 $52.6M

Operating Income

+192.1% YoY

$100.1MFY 2025

FY22 $-170.0MFY23 $-726.4MFY24 $-108.7MFY25 $100.1M

EPS (Diluted)

+125.8% YoY

$0.93FY 2025

FY22 $-4.22FY23 $-14.85FY24 $-3.60FY25 $0.93

Total Assets

-5.1% YoY

$1.32BFY 2025

FY22 $3.17BFY23 $1.82BFY24 $1.39BFY25 $1.32B

Total Debt

-15.8% YoY

$589.7MFY 2025

FY22 $2.37BFY23 $1.28BFY24 $700.0MFY25 $589.7M

Op. Cash Flow

+190.6% YoY

$170.6MFY 2025

FY22 $-34.1MFY23 $-206.3MFY24 $58.7MFY25 $170.6M

Free Cash Flow

+338.0% YoY

$156.8MFY 2025

FY22 $-149.9MFY23 $-257.9MFY24 $35.8MFY25 $156.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$742.9M -28.8%	$1.04B -0.5%	$1.05B -6.1%	$1.12B -37.0%	$1.77B +12.4%	$1.58B
Net Income	$52.6M +127.6%	$-190.6M +74.9%	$-760.5M -259.4%	$-211.6M -196.4%	$219.5M -28.2%	$305.8M
Operating Income	$100.1M +192.1%	$-108.7M +85.0%	$-726.4M -327.3%	$-170.0M -149.8%	$341.4M -22.1%	$438.5M
EPS (Diluted)	$0.93 +125.8%	$-3.60 +75.8%	$-14.85 -251.9%	$-4.22 -203.9%	$4.06 -28.5%	$5.68
Total Assets	$1.32B -5.1%	$1.39B -23.8%	$1.82B -42.4%	$3.17B +7.1%	$2.96B +2.6%	$2.88B
Total Debt	$589.7M -15.8%	$700.0M -45.4%	$1.28B -45.9%	$2.37B +169.1%	$881.2M -4.1%	$919.3M
Operating Cash Flow	$170.6M +190.6%	$58.7M +128.5%	$-206.3M -505.0%	$-34.1M -110.6%	$320.2M -40.4%	$536.9M
Free Cash Flow	$156.8M +338.0%	$35.8M +113.9%	$-257.9M -72.0%	$-149.9M -256.0%	$96.1M -75.7%	$395.0M

Get alerted when EBS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Emergent BioSolutions Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EBS

BlackRock, Inc.
$39.5M4,716,599 sh
DIMENSIONAL FUND ADVISORS LP
$25.8M3,076,646 sh
STATE STREET CORP
$24.6M2,929,238 sh
AMERICAN CENTURY COMPANIES INC
$23.2M2,770,448 sh
VANGUARD CAPITAL MANAGEMENT LLC
$18.4M2,198,839 sh
LSV ASSET MANAGEMENT
$14.2M1,695,851 sh
ACADIAN ASSET MANAGEMENT LLC
$11.3M1,344,323 sh
GEODE CAPITAL MANAGEMENT, LLC
$11.2M1,337,243 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$10.1M1,200,791 sh
OAK HILL ADVISORS LP
$9.3M1,113,338 sh

Fund	Value	Shares
BlackRock, Inc.	$39.5M	4,716,599
DIMENSIONAL FUND ADVISORS LP	$25.8M	3,076,646
STATE STREET CORP	$24.6M	2,929,238
AMERICAN CENTURY COMPANIES INC	$23.2M	2,770,448
VANGUARD CAPITAL MANAGEMENT LLC	$18.4M	2,198,839
LSV ASSET MANAGEMENT	$14.2M	1,695,851
ACADIAN ASSET MANAGEMENT LLC	$11.3M	1,344,323
GEODE CAPITAL MANAGEMENT, LLC	$11.2M	1,337,243
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$10.1M	1,200,791
OAK HILL ADVISORS LP	$9.3M	1,113,338

Companies Similar to EBS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

SRPT

Sarepta Therapeutics, Inc.

AI score

Similar quality profile · 8 shared holders

SEGALL BRYANT & HAMILL, LLC MARTINGALE ASSET MANAGEMENT L P GLOBEFLEX CAPITAL L P

TDOC

Teladoc Health, Inc.

AI score

Similar quality profile · 7 shared holders

PALISADE CAPITAL MANAGEMENT, LP ARISTEIA CAPITAL, L.L.C.Soviero Asset Management, LP

ICUI

ICU MEDICAL INC/DE

AI score

Similar quality profile · 4 shared holders

Prosight Management, LP FULLER & THALER ASSET MANAGEMENT, INC.SEGALL BRYANT & HAMILL, LLC

ORGO

Organogenesis Holdings Inc.

AI score

Similar quality profile

USNA

USANA HEALTH SCIENCES INC

AI score

Similar quality profile · 3 shared holders

SEGALL BRYANT & HAMILL, LLC LSV ASSET MANAGEMENT MEEDER ASSET MANAGEMENT INC

FTRE

Fortrea Holdings Inc.

AI score

Similar quality profile · 5 shared holders

ARISTEIA CAPITAL, L.L.C.SEGALL BRYANT & HAMILL, LLC PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.

AMS

AMERICAN SHARED HOSPITAL SERVICES

AI score

Similar quality profile · 1 shared holders

JAMES INVESTMENT RESEARCH, INC.

SIGA

SIGA TECHNOLOGIES INC

AI score

Similar quality profile · 7 shared holders

LSV ASSET MANAGEMENT Brandywine Global Investment Management, LLC SEGALL BRYANT & HAMILL, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EBS on your watchlist

Track score changes the day Emergent BioSolutions Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EBS a good stock to buy?

13F Pro's AI-powered analysis of Emergent BioSolutions Inc. (EBS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EBS are available on the EBS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EBS is classified as a small company.

Which hedge funds own EBS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EBS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Emergent BioSolutions Inc.'s investment landscape.